Gapping down
In reaction to earnings/guidance:
- CDMO -17.4%
Other news:
- ALVR -23.1% (prices offering of 20.0 mln shares of common stock at $3.75 per share)
- GPOR -9.4% (prices offering of 1.3 mln shares of common stock by selling stockholders at $95.00 per share)
- IGMS -9.3% (announces $100 mln public offering and concurrent private placement)
- ASTL -8.9% (reports Q4 results; files shelf prospectus)
- SPR -8.5% (to suspend factory operations)
- XOMA -5.2% (acquires royalty and milestone economics to Phase 3 first-in-class orphan disease asset for Niemann-Pick Disease Type C and Phase 2 oncology asset)
- CRNC -3.7% (prices $190.0 million aggregate principal amount of 1.50% convertible senior notes due 2028)
- BA -3.3% (Spirit AeroSystems news to suspend factory operations)
- IPI -1.9% (completes Phase One and provides update on Phase Two of its HB Injection Pipeline Project)
- GMAB -1.5% (Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) for ‘B-Cell Lymphomas')
- SPCE -1.1% (Board Chair Evan Lovell died unexpectedly)
- RIVN -1% (acquires mapping company Iternio)
- NVO -1% (European regulators raised safety concerns about NVO drug according to Reuters)
Analyst comments:
- DOCN -5.7% (downgraded to Underweight from Neutral at Piper Sandler)
- AA -3.2% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- TSLA -3.1% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- PAGS -2.5% (downgraded to Neutral from Buy at New Street)
- MRCY -1.7% (downgraded to Neutral from Outperform at Robert Baird)
- EQNR -1.3% (downgraded to Underweight from Equal-Weight at Morgan Stanley)